Taken together, these data imply that a prebiotic–acetate–FFAR2 molecular circuit prevents NAFLD/NASH progression by ameliorating hepatic insulin resistance and defects in lipid metabolism (Fig. 7). The gene discussed is INS; the disease is metabolic dysfunction-associated steatohepatitis.